Here, we provide demonstration of the prognostic capability of ctDNA-based KRAS mutation status in mPDAC using a large cohort consisting solely of patients with metastatic disease treated with gemcitabine and nab-paclitaxel-based therapy. Here, KRAS is linked to metastatic neoplasm.